Clinical Trials Logo

Body Weight clinical trials

View clinical trials related to Body Weight.

Filter by:

NCT ID: NCT04904406 Completed - HIV Infections Clinical Trials

Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals

AVERTAS
Start date: October 22, 2020
Phase: Phase 4
Study type: Interventional

Randomized controlled parallel open-label study in people living with HIV and at least 6 month of treatment with dolutegravir/abacavir/lamivudine prior to inclusion. Participants (n=95) are randomized to continue 3 drug-regimen dolutegravir/abacavir/lamivudine (control) or switch to two-drug regimen with dolutegravir/lamivudine (intervention). Follow-up is 48 weeks. Data is collected at baseline and week 48. Primary outcome is changes in weight from baseline of more than 2 kg. Secondary outcomes are changes in cardiac risk, composition and calcification of the heart tissue, and changes in body composition and metabolism, inflammation and coagulation. A MRI substudy is applied to focus on the cardiac adverse effects of abacavir.

NCT ID: NCT04903847 Recruiting - Obesity Clinical Trials

Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil

AVERTAS-2
Start date: February 2, 2021
Phase: Phase 4
Study type: Interventional

Randomized controlled parallel open-label study in persons living with HIV. The aim is to study weight changes in patients switching from a dolutegravir and tenofovir disoproxil containing regimen to either a dolutegravir or tenofovir disoproxil free regimen.

NCT ID: NCT04903353 Recruiting - Clinical trials for Autism Spectrum Disorder

Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole

Start date: February 1, 2022
Phase: Phase 4
Study type: Interventional

This study aims to compare two FDA approved medications (aripiprazole and risperidone) for the treatment of behavioral dysregulation in children with autism spectrum disorders. This trial, done in the context of routine clinical care, will seek to evaluate whether aripiprazole or risperidone is associated with more weight gain in children.

NCT ID: NCT04901949 Completed - Obesity Clinical Trials

The Course of Acute Pancreatitis in Patients With Different BMI Groups

Start date: September 20, 2020
Phase:
Study type: Observational

In obese (OB) patients, the presence of an increased inflammatory state in the body due to the increase in abdominal adipose tissue and increase in the frequency of gallstones and lipid levels are expected to increase the development of acute pancreatitis (AP). The effect of obesity on the clinical course of acute pancreatitis has much been attracted the attention of researchers. The aim of this study is to evaluate whether the prevalence and severity of AP, as well as Balthazar tomographic scoring, differs in BMI groups (normal, overweight, obese).

NCT ID: NCT04898439 Not yet recruiting - Cognitive Change Clinical Trials

GReen And Healthy Schools

GRAS
Start date: March 15, 2022
Phase: N/A
Study type: Interventional

This project aims to investigate the health effects of making schools greener and more biodiverse. We will mainly focus on cognitive effects, well-being, and BMI. The research hypothesis is that greening schools positively influences the health of children through more exercise and cleaner air.

NCT ID: NCT04893954 Recruiting - Clinical trials for Low Back Pain in Obese Patients After Important Weight Loss

Prospective Study on the Consequences of Weight Loss After Bariatric Surgery on Obese Patients' Spine.

SPINOB
Start date: June 3, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine how an important weight loss after bariatric surgery affects obese patients ' spine, and the effects it has on low back pain, sagittal alignment and lipomatosis .

NCT ID: NCT04893772 Completed - Weight Loss Clinical Trials

Meal Timings, Appetite, Mood and Weight Loss in Individuals on a Commercial Intermittent Fasting Programme

DASMA
Start date: June 30, 2021
Phase:
Study type: Observational

Although individuals following commercial intermittent fasting programmes consume meal replacement products during fasting days, further behavioural variables such as time of food consumption, sleep quality and duration, appetite and mood may significantly impact weight loss and intervention success. This project aims to assess behavioural patterns (dietary intake, sleep, meal timing, physical activity), mood and appetite on both fasting and non-fasting days and to investigate whether these are associated with weight loss.

NCT ID: NCT04887584 Completed - Body Weight Clinical Trials

Pulse Biomarker Discovery

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Dietary pulses, including beans, chickpeas, and lentils, are high in soluble fiber with potential benefits to human health: Pulses are moderate energy density foods, low in fat and high in dietary protein, fiber, vitamins and minerals. Moderate pulse consumption is associated with improvements in glycemic control and reduced risk of cardiovascular disease, obesity and type 2 diabetes. Measuring pulse consumption in humans is difficult, due to limitations in current methods for dietary assessment which are largely based on dietary recalls that are subject to reporting bias. Robust tools for pulse intake assessment are needed, and biomarkers of dietary pulse intake are one approach to solve this problem. The goal of this human feeding study is evaluate the presence of biomarkers of dietary pulses in human subjects.

NCT ID: NCT04886336 Recruiting - HBV Clinical Trials

The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.

HBV
Start date: June 4, 2020
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to compare the BW and metabolic profiles of CHB patient before and after shifting to TAF therapy. In this study, investigators will enroll 100 entecavir and 100 TDF treated CHB patients who will switch to TAF and then follow for one year. Demographic, liver function tests, sugar profiles, lipid profiles, ASCVD risk score, body weight, body weight, body height, and waist circumference will be checked and recorded periodically. Investigators anticipated that body weight will change significantly after switching to TAF in both entecavir and TDF group and may associated with increased risk of cardiovascular risk.

NCT ID: NCT04880486 Completed - Quality of Life Clinical Trials

Weight Training With VR in Out-Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Start date: September 18, 2019
Phase: N/A
Study type: Interventional

Using weight training with virtual reality can help after discharge patients of acute exacerbation of chronic obstructive pulmonary disease, which maintained their quality of life, and improved their exercise capacity, pulmonary function, readmission condition.